pembrolizumab – Talk Bio

ESMO 2025 KEYNOTE-671 Update: Perioperative Pembrolizumab Reinforces NSCLC Standard

4 weeks ago talkbio0Tagged ESMO Congress, Event-Free Survival, Immunotherapy, KEYNOTE-671, Keytruda, Non-Small Cell Lung Carcinoma, Overall Survival, pembrolizumab, perioperative, Standard of Care

KEYNOTE-671; pembrolizumab; KEYTRUDA; perioperative immunotherapy; NSCLC; overall survival; event-free survival; ESMO Congress; standard of care

Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer

1 month ago talkbio0Tagged checkpoint inhibitor, Co., KEYNOTE-B96 trial, Keytruda, Merck, ovarian neoplasm, Overall Survival, PD-L1, pembrolizumab, platinum-resistant, Progression-Free Survival

Merck & Co.; Keytruda; pembrolizumab; ovarian cancer; platinum-resistant; overall survival; checkpoint inhibitor; KEYNOTE-B96 trial; progression-free survival; PD-L1

Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025

1 month ago talkbio0Tagged cancer antigen therapy, checkpoint inhibitor-resistant, disease control rate, Frequency of Responses, IDO1, Immunotherapy, melanoma, Moderna, mRNA-4359, PD-L1, pembrolizumab, Phase 1/2 trial

Moderna; mRNA-4359; cancer antigen therapy; melanoma; ESMO 2025; checkpoint inhibitor-resistant; PD-L1; IDO1; objective response rate; disease control rate; immunotherapy; Phase 1/2 trial; pembrolizumab

Phase III Study: Perioperative Padcev & Keytruda Combo Significantly Improves Survival in Bladder Cancer

4 months ago talkbio0Tagged cisplatin-ineligible, enfortumab, Event-Free Survival, Keytruda, Malignant neoplasm of urinary bladder, muscle-invasive bladder cancer, Overall Survival, Padcev, pembrolizumab, perioperative, Phase III, vedotin

Padcev; Keytruda; enfortumab vedotin; pembrolizumab; phase III; bladder cancer; muscle-invasive bladder cancer; cisplatin-ineligible; perioperative; event-free survival; overall survival

IO Biotech’s cancer vaccine Cylembio narrowly misses Phase III primary endpoint in advanced melanoma, but company eyes FDA filing in 2025

4 months ago talkbio0Tagged biotech, Blackfoot language, Clinical Trials, Cylembio, Drops - Drug Form, etimupepimut, Hazard Ratio, Io satellite, Keytruda, melanoma, Overall Survival, P-Value, pembrolizumab, Phase 3, Progression-Free Survival, United States Food and Drug Administration

Cylembio; IO Biotech; melanoma; Phase 3; pivotal trial; progression-free survival (PFS); hazard ratio 0.77; p-value 0.056; Keytruda (pembrolizumab); FDA BLA; overall survival (OS) trend; IOB-013/KN-D18; NCT05155254; imsapepimut; etimupepimut; stock drop

Merus Phase 2 Data: Analysts See Strong Survival in Head & Neck Cancer, ‘Home Run’ Hopes Emerge

6 months ago talkbio0Tagged Cancer of Neck, Clinical Trials, Head, Keytruda, Merus, Overall Survival, pembrolizumab, Petosemtamab, Phase 2, Reaction, scenario

Merus; petosemtamab; Phase 2; overall survival; head and neck cancer; Pembrolizumab; Keytruda; clinical trial; analyst reaction; home run scenario

Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

7 months ago talkbio0Tagged AACR, Cancer of Neck, Clinical Trials, Event-Free Survival, Head, KEYNOTE-689 trial, Keytruda, locally advanced head, Merck, pembrolizumab, perioperative, recurrence prevention, Squamous cell carcinoma, United States Food and Drug Administration

Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA